Aesthetic Management Partners launches Exo-ME skin booster

Exo-ME extends the company's existing Cellenis PRP portfolio. Where PRP isolates platelets and growth factors, Exo-ME targets the smaller, cell-derived particles called extracellular vesicles that are naturally present in blood. The company positions this as a next step in autologous skin care, building on what the press release calls "an established, globally used Cellenis PRP platform. CEO Erik Dowell stated that Exo-ME is "a natural next step in personalized, autologous care," using the patient's own biology as the starting point rather than introducing external materials.

The device is intended for aesthetic skin and scalp protocols. It concentrates blood components entirely from the patient's own blood, with no external additives. The press release does not specify regulatory clearance status, approval pathway, or whether the system has received FDA clearance or any other regulatory authorization. It also does not state pricing, reimbursement details, or when practices can access it.

Extracellular vesicles are described in the announcement as particles that occur naturally in cells and remain under scientific study. The company designed Exo-ME to concentrate the EVs and bioactive proteins already present in a patient's own blood. The device works in aesthetic scalp and hair protocols as well, suggesting dual-use positioning in both skin and hair restoration markets.

What this means for practices

Exo-ME offers a third option in the autologous blood-derived category, alongside PRP and other concentrates. If cleared or approved, it would give practices another way to differentiate their skin-quality offerings and potentially capture patients interested in personalized, cell-derived treatments. The point-of-care model means practitioners can process blood in-office and inject the same day, similar to existing PRP workflows.

The device targets the growing skin-booster market, which has expanded as practices seek alternatives to traditional injectables. Aesthetic Management Partners sees growing interest in personalized, autologous approaches, suggesting the company believes market demand supports this category. The company also states that Exo-ME gives healthcare professionals a new option for working with a patient's own concentrated blood-derived components while building on the established Cellenis PRP platform, implying operational compatibility for practices already using Cellenis PRP.

The announcement emphasizes that Exo-ME lets practitioners incorporate a patient's own concentrated blood-derived components into individualized care. This language suggests the company is positioning the product as enabling personalization rather than a one-size-fits-all treatment.

What we don't know

The document does not disclose whether Exo-ME has received FDA clearance, approval, De Novo authorization, or any other regulatory status. It does not specify the indication or claims the company is making to regulators. There is no information on cost per treatment, required equipment, training, or how it compares operationally to existing PRP systems. The company also does not provide data on patient outcomes, how long results last, or adverse events.

Aesthetic Management Partners is based in Memphis, Tennessee, but the document does not state whether the company is publicly traded or private. The press release does not clarify whether Exo-ME is available now or pending launch, or whether practices can order it immediately.

Practitioners interested in adding Exo-ME should verify its regulatory status directly with the company and confirm what clinical evidence supports its use in their intended patient population.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.